CN101074962B - Abo血型反定型试剂 - Google Patents
Abo血型反定型试剂 Download PDFInfo
- Publication number
- CN101074962B CN101074962B CN2007101114071A CN200710111407A CN101074962B CN 101074962 B CN101074962 B CN 101074962B CN 2007101114071 A CN2007101114071 A CN 2007101114071A CN 200710111407 A CN200710111407 A CN 200710111407A CN 101074962 B CN101074962 B CN 101074962B
- Authority
- CN
- China
- Prior art keywords
- reagent
- blood group
- blood
- cell
- red blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 175
- 239000008280 blood Substances 0.000 claims abstract description 270
- 210000004369 blood Anatomy 0.000 claims abstract description 252
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 149
- 229930024421 Adenine Natural products 0.000 claims abstract description 15
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960000643 adenine Drugs 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000002441 reversible effect Effects 0.000 claims description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 49
- 239000007788 liquid Substances 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 26
- 239000011780 sodium chloride Substances 0.000 claims description 24
- 238000004321 preservation Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 19
- 210000002966 serum Anatomy 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 16
- 229930010555 Inosine Natural products 0.000 claims description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 14
- 229960003786 inosine Drugs 0.000 claims description 14
- 238000012856 packing Methods 0.000 claims description 14
- 239000006285 cell suspension Substances 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 229940097572 chloromycetin Drugs 0.000 claims description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 9
- 210000002381 plasma Anatomy 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 7
- LUVOJBWJNHWVNG-UHFFFAOYSA-N [Na].[Na].[Na].OC(=O)CC(O)(C(O)=O)CC(O)=O Chemical compound [Na].[Na].[Na].OC(=O)CC(O)(C(O)=O)CC(O)=O LUVOJBWJNHWVNG-UHFFFAOYSA-N 0.000 claims description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 7
- 235000019800 disodium phosphate Nutrition 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 7
- 238000007689 inspection Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 210000001772 blood platelet Anatomy 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000009931 harmful effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 206010018910 Haemolysis Diseases 0.000 abstract description 16
- 230000008588 hemolysis Effects 0.000 abstract description 16
- 239000007853 buffer solution Substances 0.000 abstract description 9
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 239000007979 citrate buffer Substances 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 abstract description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000004523 agglutinating effect Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000005260 corrosion Methods 0.000 description 3
- 230000007797 corrosion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000003617 erythrocyte membrane Anatomy 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000009582 blood typing Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101114071A CN101074962B (zh) | 2006-08-02 | 2007-06-18 | Abo血型反定型试剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610104071.1 | 2006-08-02 | ||
CN 200610104071 CN1924583A (zh) | 2006-08-02 | 2006-08-02 | Abo血型反定型试剂 |
CN2007101114071A CN101074962B (zh) | 2006-08-02 | 2007-06-18 | Abo血型反定型试剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101074962A CN101074962A (zh) | 2007-11-21 |
CN101074962B true CN101074962B (zh) | 2011-06-08 |
Family
ID=38976133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101114071A Active CN101074962B (zh) | 2006-08-02 | 2007-06-18 | Abo血型反定型试剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101074962B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101718794B (zh) * | 2009-11-25 | 2013-06-05 | 江阴力博医药生物技术有限公司 | ABO/RhD血型定型检测试剂卡的制备方法 |
CN101701961B (zh) * | 2009-11-25 | 2013-03-06 | 江阴力博医药生物技术有限公司 | Abo血型定型检测试剂卡的制备方法 |
CN105137096B (zh) * | 2015-08-27 | 2018-06-08 | 中国人民解放军总医院 | 一种用于血型抗体检测的试剂盒及其应用 |
CN105548581B (zh) * | 2015-12-04 | 2017-09-22 | 漯河医学高等专科学校 | 一种输血交叉配血用凝胶、制备方法及实验组合器 |
CN109946129A (zh) * | 2019-03-12 | 2019-06-28 | 江苏中济万泰生物医药有限公司 | 五分类血细胞分析仪用质控品制备方法 |
CN111713487B (zh) * | 2020-06-30 | 2021-10-08 | 上海市血液中心 | 一种试剂红细胞保存体系及其制备方法 |
CN112684191A (zh) * | 2020-12-04 | 2021-04-20 | 上海润普生物技术有限公司 | 一种ABO血型正反定型及Rh血型检测卡及其制备方法 |
CN113016775A (zh) * | 2021-05-25 | 2021-06-25 | 天津德祥生物技术有限公司 | 红细胞膜碎片冻干保护液和冻干方法及应用 |
CN114732008B (zh) * | 2022-06-13 | 2022-11-15 | 深圳瑞亚力集团有限公司 | 一种红细胞保存液及其制备方法、红细胞悬液 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1831535A (zh) * | 2006-04-24 | 2006-09-13 | 中国人民解放军军事医学科学院基础医学研究所 | Abo血型反定型试剂盒 |
-
2007
- 2007-06-18 CN CN2007101114071A patent/CN101074962B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1831535A (zh) * | 2006-04-24 | 2006-09-13 | 中国人民解放军军事医学科学院基础医学研究所 | Abo血型反定型试剂盒 |
Non-Patent Citations (2)
Title |
---|
孙爱农 等.在血清学试验中抗_A_B_溶血活性的干扰及排除.《临床检验检疫杂志》.1995,88-89. * |
孙爱农.微量板系统检测ABO和Rh_0_D_血型.《国外医学输血及血液学分册》.1994,112. * |
Also Published As
Publication number | Publication date |
---|---|
CN101074962A (zh) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101074962B (zh) | Abo血型反定型试剂 | |
Naiman et al. | The gastrointestinal effects of iron-deficiency anemia | |
US20110045455A1 (en) | Suspension medium for red blood cells | |
Lenny et al. | Transfusions to group O subjects of 2 units of red cells enzymatically converted from group B to group O | |
Javett et al. | Syndrome of hemolysis, thrombopenia and nephropathy in infancy | |
CN101592661B (zh) | 布鲁氏菌病抗体竞争酶联免疫吸附试验检测试剂盒 | |
Svejgaard et al. | Complement-fixing platelet iso-antibodies | |
CN101581726A (zh) | 新一代布鲁氏菌病抗体竞争酶联免疫吸附试验检测试剂盒 | |
CN106771182A (zh) | 牛布鲁氏菌IgM亚型抗体间接ELISA检测试剂盒 | |
CN106556701A (zh) | 羊布鲁氏菌间接elisa抗体检测试剂盒 | |
CN1924583A (zh) | Abo血型反定型试剂 | |
Macdougall | Red cell metabolism in iron-deficiency anemia | |
CN107202898A (zh) | 用于筛查血型不规则抗体的试剂盒 | |
CN1206537C (zh) | 试剂红细胞 | |
CN111713487B (zh) | 一种试剂红细胞保存体系及其制备方法 | |
Lauf et al. | Solubilization and structural integrity of the human red cell membrane | |
US8623659B2 (en) | Sickle confirm modified hemoglobin solubility test | |
Bialek et al. | Distribution and quantity of leukocyte antigens in the formed elements of the blood | |
Berlin et al. | Anti-“i” antibody and hemolytic anemia associated with spontaneous cytomegalovirus mononucleosis | |
Bartova et al. | Changes in the group A antigen in a case of acute myeloblastic leukemia | |
Wiener | Intragroup incompatibility with respect to the Hr blood factors as a cause of minor hemolytic transfusion reactions | |
COOKE | PROTEOLYTIC LEUKOCYTIC ENZYME IN LEUKEMIA: A STUDY MADE BY A QUANTITATIVE METHOD | |
Staples et al. | Development and use of pediatric frozen red cell packs | |
CN112684176A (zh) | 一种Rh血型抗原检测卡及制备方法 | |
CN112684191A (zh) | 一种ABO血型正反定型及Rh血型检测卡及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Kinghawk Pharmaceutical Co., Ltd. Assignor: Cao Jianrong|Zhang Zha Contract record no.: 2011990000640 Denomination of invention: ABO blood group inverse reagent Granted publication date: 20110608 License type: Exclusive License Open date: 20071121 Record date: 20110714 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151021 Address after: 100176, 7, Cheng Cheng street, Beijing economic and Technological Development Zone Patentee after: Beijing Kinghawk Pharmaceutical Co., Ltd. Address before: 100176 No. 7 Yuncheng street, Beijing economic and Technological Development Zone Patentee before: Zhang Zha Patentee before: Cao Jianrong |